In Conversation with Edith Lecomte Norrant, Innovation Tech Science Dr at UCB

About Edith:
Innovation and New Technology Development Director
Scientific External Partnership Director In UCB Biopharma (Belgium)
Global Process Development & Industrialization (DS &DP) New Technology Director (UCB Biopharma)
Director of Process & Industrialization Department for API (Belgium) (UCB Biopharma)
Deputy Manager of Industrial Director for 3 Chemical Plants (France, UK) (Rhodia)
Pilot Plant Manager for API production (Pierre Fabre)
Research and Development Project Manager for API (US, Europe [France, UK, Spain, Belgium…])
Project Manager of Industrial Projects for API (US, Argentina, Europe [France, UK, Spain, …])
Expert in Chemical Engineering for Fine Chemical and Pharmaceutical Products
Department Head (France, USA)
International Experience (US, South America, Russia, Europe)
National Researcher (CNRS-ENSIC in France).
HDR in Chemical Engineering (Toulouse University /France)

Specialties: Expert in Chemical Engineering for Chemistry and biological process to develop new pharmaceutical drugs

About UCB:
UCB – Inspired by patients. Driven by science. At UCB, we put our heart, soul and skills into making a difference for people living with severe diseases. We look to transform patients’ lives by pushing the boundaries of what is possible. With us, our talents makes the most of who they are, unlocking innovation and setting new standards for patients.

Everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?”
And to find the answers, we connect globally with patients and their families living with the physical and social burdens of severe disease. These connections give us new perspectives, drive our innovation, and offer a hope for a new generation of therapies that will help to transform lives.

UCB – The Facts

With more than 7500 employees in approximately 40 countries, we are a global biopharmaceutical company headquartered in Brussels, Belgium which invests more than 20% of revenue in cutting-edge scientific research to meet unmet patient needs.
A few other reasons that make UCB an amazing place to work:
– Promising pipeline that includes several novel molecules and no major patent expiration in the next decade;
– 23% of 2017 revenue reinvested into Research & Development
– 2017 Key Financials: €4.5 billion global revenue

Specialties: Neurology, Immunology